References
- Karlin L, Soulier J, Chandesris O, etal. Clinical and biological features of t(4;14) multiple myeloma: a prospective study. Leuk Lymphoma 2011;52:238–246.
- Kaufmann H, Ackermann J, Baldia C, etal. Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma. Leukemia 2004;18:1879–1882.
- Gertz MA, Lacy MQ, Dispenzieri A, etal. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and −17p13 in myeloma patients treated with high-dose therapy. Blood 2005;106:2837–2340.
- Avet-Loiseau H, Soulier J, Fermand JP, etal. Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone. Leukemia 2010;24:623–628.
- Avet-Loiseau H, Leleu X, Roussel M, etal. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol 2010;28:4630–4634.
- Gutierrez NC, Castellanos MV, Martin ML, etal. Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis. Leukemia 2007;21:143–150.
- Fonseca R, Bergsagel PL, Drach J, etal. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009;23:2210–2221.
- San-Miguel J, Mateos MV, Gutierrez NC. Risk stratification in the era of novel therapies. Cancer J 2009;15:457–464.